Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

A Clinical Trial to Evaluate the Safety and Immunogenicity of rVSV∆G-MARV-GP Vaccine in Adults in Good General Health

27. oktober 2026 oppdatert av: International AIDS Vaccine Initiative

En fase 1 randomisert, observatør-blind, placebo-kontrollert, dose-eskalerende klinisk studie for å evaluere sikkerheten og immunogeniteten til rVSVΔG-MARV-GP-vaksinen hos voksne i god generell helse

A Phase 1 Randomized, Observer Blind, Placebo-controlled, Dose-escalation and dose expansion Clinical Trial to Evaluate the Safety and Immunogenicity of rVSV∆G-MARV-GP Vaccine in Adults in Good General Health

Studieoversikt

Status

Aktiv, ikke rekrutterende

Detaljert beskrivelse

This is a observer-blind, Phase 1 Randomized, Placebo-controlled, Dose-escalation Clinical Trial to Evaluate the Safety and Immunogenicity of rVSV∆G-MARV-GP Vaccine in Adults in Good General Health. The study is a dose escalation study that will administer 4 different dose levels to 4 different groups. The lowest dose level will be given and then a safety assessment will occur before escalation to the next dose level. This gradual dosing followed by a safety assessment will be repeated at each dose level.

Approximately 112 participants will be given vaccine (rVSV∆G-MARV-GP) or placebo.

This IAVI C104 study will look at the safety, tolerability and immunogenicity of the rVSV Marburg virus vaccine.

Studietype

Intervensjonell

Registrering (Antatt)

112

Fase

  • Fase 1

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

    • District of Columbia
      • Washington D.C., District of Columbia, Forente stater, 20052
        • George Washington University
    • Kansas
      • Lenexa, Kansas, Forente stater, 66219
        • Johnson County Clin-Trials

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år til 50 år (Voksen)

Tar imot friske frivillige

Ja

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria

  1. Adults in good general health
  2. Participants who are 18 to 50 years of age
  3. Willing to comply with the requirements of the protocol and available for follow-up for the planned duration of the study
  4. Willing to undergo HIV testing, risk reduction counseling, and receive HIV test results
  5. All sexually active participants must consistently use male or female condoms with all sexual partners for 3 months following IP administration
  6. All individuals of childbearing potential engaging in sexual activity that could lead to pregnancy must commit to use an effective method of contraception from at least 2 weeks before and continue until 3 months following receipt of vaccine/placebo
  7. All individuals of childbearing potential must be willing to undergo urine pregnancy tests at time points indicated in the Schedule of Activities (SOA)
  8. All participants must be willing to forgo donation of blood or any other tissues from screening onward throughout the course of the study

Exclusion Criteria

  1. Any clinically relevant abnormality on history or examination including:

    history of immunodeficiency or autoimmune disease history of splenectomy history of malignancy in the past 5 years use of corticosteroids, immunosuppressive, anticancer, or other medications considered significant by the Investigator within the previous 6 months body mass index (BMI) ≥ 35.0 kg/m2

  2. Any clinically significant acute or chronic medical condition that is considered progressive or in the opinion of the Investigator makes the participant unsuitable for participation in the study

  3. Individuals who are pregnant or breastfeeding

  4. Bleeding disorder that was diagnosed by a physician

  5. Infectious disease: Confirmed HIV-1 or HIV-2 infection, chronic active hepatitis B infection, current hepatitis C infection, active syphilis, or medically diagnosed long COVID 19 Syndrome. Also excluded are participants with active, serious infections requiring parenteral antibiotic, antiviral, or antifungal therapy within 30 days prior to enrollment.

  6. Any abnormal laboratory parameters at screening per protocol.

  7. Receipt of live attenuated influenza vaccine within the previous 14 days, any other live attenuated vaccine within the previous 30 days or planned receipt within 30 days after vaccination with IP; or receipt of non-live attenuated vaccine within the previous 14 days or planned receipt within 14 days after vaccination with IP, including COVID-19 vaccines

  8. Receipt of blood transfusion or blood-derived products within the previous 3 months

  9. Prior potential exposure to Marburg Virus, or a medical history of hemorrhagic fever

  10. Prior receipt of any VSV-vectored vaccine, any Marburg vaccine, or any vaccine containing a filovirus component. Prior receipt of monoclonal or polyclonal antibodies directed against Marburg or other filovirus in the past 12 months

  11. Current participation in another clinical trial, within 3 months prior to enrollment.

  12. History of severe local or systemic reactogenicity to vaccines, or severe allergy to food or medications, and/or allergy to any component of this vaccine.

  13. Neuropsychiatric condition or substance abuse that compromises safety of the participant and precludes compliance with the protocol

  14. Current or planned occupational (medical care, childcare) or household contact (residing in the same household) from screening through 3 months after IP administration with any individual at increased risk from exposure to a live viral vaccine including infants ≤ 1 year of age, adults ≥75 years of age, or immunocompromised individuals.

  15. In the opinion of the PI, it is not in the best interest of the participant to participate in the trial

  16. A history of long-term treatment (≥ 4 weeks) for arthritis

  17. Participants currently experiencing a rash or who have a history of severe, chronic, or frequent rash will be excluded.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Forebygging
  • Tildeling: Randomisert
  • Intervensjonsmodell: Enkeltgruppeoppdrag
  • Masking: Trippel

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: rVSV∆G-MARV-GP

rVSV∆G-MARV-GP

Placebo komparator: Placebo/Diluens

Placebo

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Safety and tolerability of rVSV∆G-MARV-GP vaccination: solicited reactogenicity
Tidsramme: 14 Days

Occurrence, onset, duration, and severity of local and systemic solicited adverse events within 14 days following vaccination

14 Days
Safety and tolerability of rVSV∆G-MARV-GP vaccination: unsolicited reactogenicity
Tidsramme: 28 days

Occurrence, onset, duration, severity, and relationship to IP of unsolicited adverse events, including safety laboratory parameters, within 28 days following vaccination

28 days
Safety and tolerability of rVSV∆G-MARV-GP vaccination: SAEs and AESIs
Tidsramme: 7 Months

Occurrence, onset, duration, severity, and relationship to IP of SAEs and AESIs throughout the study period

7 Months

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
MARV-GP-specific serum antibody responses
Tidsramme: Throughout the study, up to 6 months after immunisation

Proportion of participants with binding antibody responses to MARV-GP

Throughout the study, up to 6 months after immunisation
MARV-GP-specific serum antibody responses magnitude and duration
Tidsramme: Throughout the study, up to 6 months after immunisation

Magnitude and duration of binding antibody to MARV-GP throughout the full study period (1 week, 2 weeks, 4 weeks, 2 months, 3 months, 6 months after immunization)

Throughout the study, up to 6 months after immunisation
MARV-GP-specific serum antibody neutralization
Tidsramme: Throughout the study, up to 6 months after immunisation

Proportion of participants with neutralizing antibody against Marburg virus as measured by PRNT assay

Throughout the study, up to 6 months after immunisation
MARV-GP-specific serum antibody magnitude and duration of neutralization
Tidsramme: Throughout the study, up to 6 months after immunisation

Magnitude and duration of neutralizing antibody against Marburg virus as measured by PRNT assay throughout the full study period (1 week, 2 weeks, 4 weeks, 2 months, 3 months, 6 months after immunization)

Throughout the study, up to 6 months after immunisation

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

27. mars 2026

Primær fullføring (Antatt)

1. april 2027

Studiet fullført (Antatt)

1. oktober 2027

Datoer for studieregistrering

Først innsendt

11. februar 2026

Først innsendt som oppfylte QC-kriteriene

19. februar 2026

Først lagt ut (Faktiske)

23. februar 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

30. oktober 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

27. oktober 2026

Sist bekreftet

1. oktober 2026

Mer informasjon

Begreper knyttet til denne studien

Andre studie-ID-numre

  • IAVI C104
  • 75A50121C00077 (Annet stipend/finansieringsnummer: BARDA)

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Ja

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere